AI Engines For more Details: Perplexity Kagi Labs You
Antibacterial Action: Sulfameter belongs to the sulfonamide class of antibiotics, which inhibit the growth and reproduction of bacteria by interfering with the synthesis of folic acid, a crucial component for bacterial growth. By blocking folic acid production, sulfameter effectively prevents the bacteria from multiplying and eventually leads to their death.
Treatment of Bacterial Infections: Sulfameter is commonly used to treat a wide range of bacterial infections in livestock, including respiratory tract infections, gastrointestinal infections, urinary tract infections, and other systemic infections caused by susceptible organisms. These infections can significantly impact animal health and productivity if left untreated.
Dosage and Administration: Sulfameter is typically administered orally in the form of medicated feed, water, or bolus. The dosage and duration of treatment depend on factors such as the severity of the infection, the species of animal, and the susceptibility of the causative bacteria. It is essential to follow the veterinarian's or manufacturer's instructions regarding dosage, administration, and withdrawal periods to ensure effective treatment and minimize the risk of antimicrobial resistance.
Adverse Effects: While sulfameter is generally well-tolerated in livestock when used as directed, adverse effects may occur in some cases. Common side effects may include gastrointestinal disturbances such as diarrhea, vomiting, and decreased appetite. Allergic reactions or hypersensitivity responses may also occur rarely.
Precautions and Considerations: Sulfameter should be used cautiously in animals with known hypersensitivity to sulfonamide antibiotics or those with pre-existing liver or kidney dysfunction. Care should be taken to avoid overdosage, as it may lead to toxicity or adverse effects. Additionally, adequate water intake should be ensured during treatment to prevent dehydration.
Withdrawal Periods: In food-producing animals, including livestock, it is essential to observe withdrawal periods to ensure that residues of sulfameter are below acceptable levels in animal products such as meat and milk before they enter the food chain. Adherence to withdrawal periods helps to ensure food safety and compliance with regulatory requirements.
Drug Interactions: Sulfameter may interact with other medications or substances, including other antibiotics, sulfa drugs, or substances that affect renal function. It is essential to consult with a veterinarian before administering sulfameter concurrently with other drugs to avoid potential interactions or adverse effects.
Resistance: Like other antibiotics, the overuse or misuse of sulfameter can contribute to the development of bacterial resistance. Therefore, it is crucial to use sulfameter judiciously and only when indicated to preserve its effectiveness for the treatment of bacterial infections in livestock and poultry.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.6 | 0.3 | 11 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3 | 2.1 | 0.43 |
| Allergies | 6.2 | 2.7 | 1.3 |
| Allergy to milk products | 1.9 | 1.6 | 0.19 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 5.9 | 5.7 | 0.04 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.2 | 1.3 | 1.46 |
| Ankylosing spondylitis | 3.8 | 1.6 | 1.37 |
| Anorexia Nervosa | 1.4 | 2.3 | -0.64 |
| Antiphospholipid syndrome (APS) | 0.8 | 0.3 | 1.67 |
| Asthma | 4.8 | 3.1 | 0.55 |
| Atherosclerosis | 2 | 1.3 | 0.54 |
| Atrial fibrillation | 3.1 | 1.9 | 0.63 |
| Autism | 8.7 | 7.7 | 0.13 |
| Autoimmune Disease | 1.2 | 0.8 | 0.5 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.9 | 1.9 | |
| Bipolar Disorder | 2.2 | 1.4 | 0.57 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.8 | 0.8 | |
| Cancer (General) | 0.9 | 2 | -1.22 |
| Carcinoma | 4.8 | 2.6 | 0.85 |
| Celiac Disease | 2.1 | 3.9 | -0.86 |
| Cerebral Palsy | 1.5 | 1.3 | 0.15 |
| Chronic Fatigue Syndrome | 4.7 | 4.3 | 0.09 |
| Chronic Kidney Disease | 4.7 | 2.3 | 1.04 |
| Chronic Lyme | 0.4 | 0.8 | -1 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.7 | -0.31 |
| Chronic Urticaria (Hives) | 1.6 | 0.8 | 1 |
| Coagulation / Micro clot triggering bacteria | 1.7 | 1.3 | 0.31 |
| Cognitive Function | 3.1 | 1.4 | 1.21 |
| Colorectal Cancer | 6.4 | 2.1 | 2.05 |
| Constipation | 1.8 | 0.7 | 1.57 |
| Coronary artery disease | 2.3 | 1.7 | 0.35 |
| COVID-19 | 8.6 | 8.3 | 0.04 |
| Crohn's Disease | 7.6 | 5.1 | 0.49 |
| Cushing's Syndrome (hypercortisolism) | 0.6 | -0.6 | |
| cystic fibrosis | 1 | 1.6 | -0.6 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 2 | 1.4 | 0.43 |
| Denture Wearers Oral Shifts | 1.3 | 1.3 | |
| Depression | 10.2 | 7.8 | 0.31 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.8 | 1.2 | 0.5 |
| Endometriosis | 3 | 2.1 | 0.43 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.1 | 2.2 | 0.41 |
| erectile dysfunction | 1.2 | 0.3 | 3 |
| Fibromyalgia | 2.4 | 1 | 1.4 |
| Functional constipation / chronic idiopathic constipation | 4.2 | 3.3 | 0.27 |
| gallstone disease (gsd) | 3.3 | 1.5 | 1.2 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 1.2 | 0.25 |
| Generalized anxiety disorder | 3.1 | 1.5 | 1.07 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.5 | 0.4 | 5.25 |
| Graves' disease | 1.9 | 3 | -0.58 |
| Gulf War Syndrome | 0.4 | 1.5 | -2.75 |
| Halitosis | 1.6 | 0.3 | 4.33 |
| Hashimoto's thyroiditis | 3.8 | 2 | 0.9 |
| Heart Failure | 3.8 | 1.7 | 1.24 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 0.9 | 0.6 | 0.5 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.6 | 0.17 |
| hyperglycemia | 2.2 | 2.1 | 0.05 |
| Hyperlipidemia (High Blood Fats) | 1.3 | 0.3 | 3.33 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5 | 4.4 | 0.14 |
| Hypothyroidism | 0.4 | 0.7 | -0.75 |
| Hypoxia | 3 | 0.3 | 9 |
| IgA nephropathy (IgAN) | 1.9 | 2.8 | -0.47 |
| Inflammatory Bowel Disease | 7 | 7.3 | -0.04 |
| Insomnia | 1.6 | 3.1 | -0.94 |
| Intelligence | 1.1 | 1.1 | |
| Intracranial aneurysms | 1.4 | 0.3 | 3.67 |
| Irritable Bowel Syndrome | 8 | 4.8 | 0.67 |
| ischemic stroke | 2.7 | 1.4 | 0.93 |
| Liver Cirrhosis | 7 | 5.1 | 0.37 |
| Long COVID | 5.9 | 6.8 | -0.15 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.5 | 1.6 | -0.07 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.3 | 0.6 | 1.17 |
| ME/CFS with IBS | 0.6 | 1.8 | -2 |
| ME/CFS without IBS | 1.7 | 1.8 | -0.06 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.1 | 0.9 | 0.22 |
| Metabolic Syndrome | 8 | 7.4 | 0.08 |
| Mood Disorders | 10.1 | 6.3 | 0.6 |
| multiple chemical sensitivity [MCS] | 1 | 0.1 | 9 |
| Multiple Sclerosis | 6.4 | 3.3 | 0.94 |
| Multiple system atrophy (MSA) | 1.6 | 0.7 | 1.29 |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 0.3 | 3.1 | -9.33 |
| Neuropathy (all types) | 1.1 | 1.8 | -0.64 |
| neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.5 | 4.5 | 0 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 10.8 | 8.1 | 0.33 |
| obsessive-compulsive disorder | 4.8 | 3.3 | 0.45 |
| Osteoarthritis | 2.1 | 1.6 | 0.31 |
| Osteoporosis | 2.3 | 1.9 | 0.21 |
| pancreatic cancer | 1 | 0.3 | 2.33 |
| Parkinson's Disease | 8.1 | 4.3 | 0.88 |
| Polycystic ovary syndrome | 4.9 | 3 | 0.63 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.2 | 0 |
| Primary sclerosing cholangitis | 2.2 | 1.9 | 0.16 |
| Psoriasis | 3.5 | 1.9 | 0.84 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.5 | 3.2 | 1.34 |
| Rosacea | 1.1 | 0.5 | 1.2 |
| Schizophrenia | 6 | 3 | 1 |
| scoliosis | 0.4 | 0.8 | -1 |
| Sjögren syndrome | 2.6 | 2.5 | 0.04 |
| Sleep Apnea | 1.9 | 1.6 | 0.19 |
| Slow gastric motility / Gastroparesis | 1.3 | 0.3 | 3.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.3 | 4.33 |
| Stress / posttraumatic stress disorder | 3.2 | 3.1 | 0.03 |
| Systemic Lupus Erythematosus | 3.7 | 1.8 | 1.06 |
| Tic Disorder | 1.2 | 1.2 | 0 |
| Tourette syndrome | 1.3 | 0.3 | 3.33 |
| Type 1 Diabetes | 3.4 | 3.3 | 0.03 |
| Type 2 Diabetes | 8.4 | 6.4 | 0.31 |
| Ulcerative colitis | 4.6 | 5.3 | -0.15 |
| Unhealthy Ageing | 4.8 | 1.9 | 1.53 |
| Vitiligo | 2.1 | 1.1 | 0.91 |
